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Cunfeng Song, Yugang Li, Tianliang Li, Yuming Yang, Zhicheng Huang,  
Jesús Martinez de la Fuente, Jian Ni, and Daxiang Cui*
Nanocarriers for chemo-photothermal therapy suffer from insufficient retention 
at the tumor site and poor penetration into tumor parenchyma. A smart drug-
dye-based micelle is designed by making the best of the structural features of 
small-molecule drugs. P-DOX is synthesized by conjugating doxorubicin (DOX) 
with poly(4-formylphenyl methacrylate-co-2-(diethylamino) ethyl methacrylate)-
b-polyoligoethyleneglycol methacrylate (P(FPMA-co-DEA)-b-POEGMA) via 
imine linkage. Through the π–π stacking interaction, IR780, a near-infrared 
fluorescence dye as well as a photothermal agent, is integrated into the micelles 
(IR780-PDMs) with the P-DOX. The IR780-PDMs show remarkably long blood 
circulation (t1/2β = 22.6 h). As a result, a progressive tumor accumulation and 
retention are presented, which is significant to the sequential drug release. 
Moreover, when entering into a moderate acidic tumor microenvironment, 
IR780-PDMs can dissociate into small-size conjugates and IR780, which 
obviously increases the penetration depth of drugs, and then improves the 
lethality to deep-seated tumor cells. Owing to the high delivery efficiency and 
superior chemo-photothermal therapeutic efficacy of IR780-PDMs, 97.6% 
tumor growth in the A549 tumor-bearing mice is suppressed with a low dose 
of intravenous injection (DOX, 1.5 mg kg−1; IR780, 0.8 mg kg−1). This work 
presents a brand-new strategy for long-acting intensive cancer therapy.
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tumor site.[1] Even the drugs are loaded by 
nanocarriers, however, owing to the in vivo 
ubiquitous biological barriers (e.g., phago-
cytic sequestration, protein adsorption, 
and renal clearance),[2] only 0.7% of the 
injected dose can be effectively enriched 
in a solid tumor. Hence, the requirement 
to potent nanocarriers with high delivery 
efficiency becomes increasingly urgent.
Since the ability of being tailored from 
original polymers to achieve in vivo sys-
temic administration, polymer micelles 
possess several unique properties, 
including toilless drug loading, control-
lable size tailoring, and adjustable func-
tion endowing, which makes them become 
one kind of ideal nanocarriers.[3] In order 
to obtain good therapeutic efficacy, blood 
circulation is one of the most important 
requirements.[4] Generally, long circulation 
of the micelles can promote the accumu-
lation and retention of drugs at the tumor 
sites through the enhanced permeability 
and retention effect.[5] Recently, numerous 
studies have been devoted to the surface 
modification of PEGylate and the size/charge adjustment of 
micelles to prolong the blood circulation time.[6] Nevertheless, 
these strategies can hardly cope with the fast clearance of drug 
caused by the early leakage to unexpected sites. Chemical cross-
linking was used to stabilize polymeric micelles, but it does not 
necessarily promote the drug retention within the micelles.[7]
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The emerging nanocarriers tend to be more efficient and reli-
able for single-drug therapy of cancers. Nanocarriers can 
protect the bioactive components from degradation in physi-
ological fluids, and provide a controlled release of drugs at the 
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As is well known, rapid tumor angiogenesis-induced heterog-
enous vasculature will make a tumor microenvironment to be 
lack of nutrients (e.g., oxygen and glucose).[8] In order to adapt 
to the extremely harsh bioenvironment, most of the tumor 
cells usually evolve stronger viability. Therefore, the applica-
tion of mono-chemotherapy is fairly limited due to the low 
therapeutic efficacy caused by drug resistance.[9] Photothermal 
therapy (PTT), which thermally ablates tumor cells by directly 
converting light radiation into heat energy with the PTT agents, 
is regarded as a preferable method for eliminating malignant 
cells.[10] The PTT agents strongly absorb near-infrared (NIR) 
light (650–900 nm) that can penetrate deep tissue without 
causing any damage.[11] Among them, IR780, a stable NIR hep-
tamethine dye, has attracted tremendous attention for its out-
standing photothermal conversion and remarkable properties 
in NIR fluorescence/photoacoustic (PA) imaging.[12] Further-
more, by combining with PTT, the efficacy of chemotherapy 
with a low dose can be obviously enhanced.[13] This is especially 
effective for DNA damaging chemodrugs (e.g., doxorubicin 
(DOX)), because the NIR-generated hyperthermia can interfere 
with DNA repair.[14] Since it integrates two therapeutic methods 
on a single platform, the chemo-phototherapy shows a “1+1>2” 
effect to inhibit tumor growth by the synergistic enhancement 
interaction.[15] Unfortunately, due to the tumor-associated fibro-
blasts, high interstitial fluid pressure, and dense extracellular 
matrix, most of the nanocarriers are restricted in perivascular 
regions.[16] As a result, the locally inhomogenous distribution of 
nanocarriers will trigger the incomplete killing of tumor cells, 
particularly at drug/heat-omitted areas. Even worse, the current 
dye-based nanocarriers lack a stimulus-responsive “switch” to 
overcome these hindrances in deep tumor delivery.[17]
In this work, a smart drug-dye-based micelle with ultrahigh 
pH-sensitivity was employed to improve the therapeutic efficacy 
of malignant tumor. IR780-PDMs (≈142 nm) were prepared by 
the self-assembly of P-DOX and the loading of IR780. The non-
covalent π–π stacking interaction between conjugated DOX and 
IR780 increased the retention of the two small-molecule drugs 
in polymeric micelles. Comparing with the nonconjugated 
counterparts (IR780-Ms) constructed by the block polymer 
poly(2-(diethylamino) ethyl methacrylate)-b-polyoligoethylene-
glycol methacrylate (PDEA-b-POEGMA), IR780-PDMs showed 
obviously enhanced tumor accumulation and retention due to 
their long systemic circulation. As shown in Figure 1, there are 
two stages of the pH response in the delivery process. First, 
after arriving at the tumor sites (pH 6.5–7.0), IR780-PDMs 
dissociated into small-size conjugates and IR780. It has been 
found that the ultrasmall particles (≈10 nm) are inherently 
favorable to the deep penetration into tumor due to their low 
diffusional hindrance.[18] Second, once P-DOX is endocytosed 
into the intracellular endo/lysosome (pH 4.5–6.0), its aromatic 
imine linkage can be hydrolyzed,[19] which leads to a stimuli-
triggered release of DOX. Such a combinatorial approach can 
Adv. Funct. Mater. 2020, 30, 1906309
Figure 1. Schematic illustration of the self-assembling and π–π stacking formation of IR780-PDMs with ultrahigh pH sensitivity, and their application 
in superior chemo-photothermal therapy.
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overcome various physiological and pathological barriers to 
optimize the drug delivery efficiency for chemo-photothermal 
therapy. In addition, being different from traditional micelles 
which always need multiple dosage to maintain effective drug 
concentration at the tumor tissue,[20] the sustained drug release 
of our system after a single-dose injection can effectively reduce 
the dosing frequency and prevent the recurrence of malignant 
tumor owing to the long-term tumor retention. The therapeutic 
and biosafe benefits of IR780-PDMs are further demonstrated 
in the present study as well.
2. Results and Discussion
2.1. Synthesis and Characterization of P-DOX
The copolymer backbone of P-DOX was synthesized via 
reversible addition-fragmentation chain-transfer polymeriza-
tion. The synthesis routes of P-DOX are shown in Figure S1A 
(Supporting Information). 1H NMR spectra of all the polymers 
reveal that all the proton signals have a good correspondence 
with their molecular structures (Figure S1B, Supporting Infor-
mation). After the Schiff base reaction between the amine 
group of DOX and the aldehyde group of poly(4-formylphenyl 
methacrylate-co-2-(diethylamino) ethyl methacrylate)-b-polyoli-
goethyleneglycol methacrylate (P(FPMA-co-DEA)-b-POEGMA), 
an increase of molecular weight can be observed, as shown 
in Figure S2 (Supporting Information). The number-average 
molecular weights (Mn) and dispersity (PDI, polydispersity 
index) were analyzed by gel permeation chromatography (GPC; 
Table 1). Fourier transform-infrared spectroscopy (FT-IR) and 
UV-vis spectra were used to characterize P-DOX, which con-
firms the successful synthesis of this conjugate (Figures S3 and 
S4, Supporting Information).
The self-assembly of P-DOX into micellar structures in 
phosphate buffer (PB) solution (pH 7.4) was observed by trans-
mission electron microscopy (TEM; Figure 2A). Moreover, the 
scattering intensities of P-DOX with the concentration ranging 
from 0.001 to 1 mg mL−1 were recorded by NanoBrook Omni. 
As shown in Figure 2B, the inflection point corresponding to 
the critical micelle concentration (CMC) is 0.029 mg mL−1, 
which indicates that P-DOX was aggregated in the form of 
micelles (PDMs) even at very low concentration. To investigate 
the pH-triggered disassembly, PDMs were incubated in a series 
of PB solutions with pH values in the range from 7.4 to 6.3. A 
sharp size variation from 126.3 ± 5.6 nm at pH 7.4 to 12.1 ± 
0.9 nm at pH 6.6 within a very narrow range of acidity was 
measured by dynamic light scattering (DLS; Figure 2C). When 
the pH of medium decreased to 6.6, PDMs dissociated into 
P-DOX conjugates (Figure 2D), due to the change of hydro-
philic–lipophilic balance induced by the protonated PDEA 
blocks. This conjecture was proven by the variation of zeta 
potential from −0.2 ± 0.1 to 18.8 ± 1.2 mV (Figure 2E). In addi-
tion, zeta potential of 23.1 ± 0.6 mV at pH 5.0 suggests that the 
P-DOX conjugates can be easily and well dispersed into endo/
lysosome.
2.2. Stability, Photothermal Efficiency, and Responsive  
Chemodrug Release of IR780-PDMs
Using acetone as a co-solvent, IR780 dyes were dropped into 
P-DOX solution during the self-assembly process followed by 
the evaporation of acetone. The CMC value of P-DOX with 
IR780 is 0.022 mg mL−1, it is probably because the stacking 
interaction with the hydrophobic molecule makes the aggre-
gation be easier to form the micelles (Figure S5A, Supporting 
Information). As shown in Figure 2F, after encapsulation, the 
hydrodynamic diameter of IR780-PDMs was 142.8 ± 3.7 nm. 
The in vitro stability of IR780-PDMs was also investigated by 
DLS (Figure S5B, Supporting Information). The particle size 
of IR780-PDMs did not show significant variation after being 
incubated in both PBS and 10% fetal bovine serum (FBS) 
medium at pH 7.4 for 48 h. The pH of medium was instan-
taneously adjusted to 6.6 by adding 1 m HCl. Then, the time-
dependent decrease of scattering intensity was measured, 
which reveals that the size transition of IR780-PDMs at acidic 
pH can be accomplished within 10 min (Figure S6, Supporting 
Information). Compared with our previous work,[21] this rela-
tive long dissociation time might be attributed to the strong 
π–π stacking effect among the polymeric chains. Meanwhile, 
the dissociation of IR780-PDMs into small particles around 
10 nm can be observed in Figure S7 (Supporting Information).
The photothermal behavior of IR780-PDMs was evaluated by 
monitoring the temperature variation under continuous laser 
irradiation (808 nm, 1 W cm−2). The visual images (Figure 2G) 
shows that there is a negligible change in the temperature of 
phosphate-buffered saline (PBS). However, a distinct change of 
the temperature of IR780-PDMs, which depends on the con-
centration of IR780, is observed. Figure 2H presents that the 
temperature of IR780-PDMs increased 17.5 °C at an equivalent 
concentration of 12 µg mL−1 of IR780 within 5 min of irradia-
tion. The heat converted from the laser can deal irreversible 
damage to cancer cells.
The drug loading percentages (DL) of DOX and IR780 were 
6.8 ± 0.6% and 3.6 ± 0.4%, respectively. An effective anticancer 
agent should respond to a tumor-relative stimulus and then 
release drugs for therapy. In order to estimate the stimuli-sensi-
tive drug releasing capacity, IR780-PDMs were dialyzed against 
PBS of different pH values. As shown in Figure 2, only 12.1% 
DOX was released from IR780-PDMs at pH 7.4 for 48 h, sug-
gesting that most of DOX were embedded into micelles during 
blood circulation. By contrast, IR780-PDMs showed a much 
faster release at pH 5.0, up to 76.3%, which was even higher 
than the release at pH 6.6. The cumulative release of DOX from 
IR780-PDMs was remarkably accelerated in acidic environ-
ment, which can be attributed to the breaking of the acid-labile 
imine bonds. In addition, after the irradiation of 808 nm laser 
(1 W cm−2, 5 min), the release of DOX at pH 5.0 was further 
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Table 1. Characteristics of the polymers.
Sample Mna) PDIa)
P(FPMA-co-DEA) 6920 1.27
P(FPMA-co-DEA)-b-POEGMA 34 579 1.34
P-DOX 38 168 1.40
a)Determined by GPC in DMF using PMMA as standards.
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increased to 83.9%, which is probably because the light-induced 
heat facilitated the hydrolysis of imine linkage and molecular 
diffusion. Therefore, the pH-dependent release property of 
IR780-PDMs is conducive to the intracellular targeting drug 
delivery. As shown in Figure S8 (Supporting Information), the 
cumulative release amount of the loaded IR780 was less than 
15% at pH 7.4 within 48 h. However, the corresponding value 
at pH 6.6 increased up to 82.2%, which can be attributed to 
the dissociation of nanocarriers. Under laser irradiation, the 
release was most likely accelerated by the heat-triggered destruc-
tion of π–π stacking interaction and the molecular diffusion.
2.3. Cytotoxicity and Cellular Uptake of IR780-PDMs
In vitro cytotoxicity was evaluated by 3-(4,5-dimethyl-2-thiazolyl)-
2,5-diphenyl tetrazolium bromide (methyl thiazolyltetrazolium) 
(MTT) assay on A549 cell line. As shown in Figure 3A, due to 
the excellent biocompatibility of copolymer backbone P(FPMA-
co-DEA)-b-POEGMA, no obvious cell death was observed in 
this group. Whereas, after the treatments with various drug 
formulations for 24 h, the cell viability decreased with the 
increase of DOX concentration from 0.5 to 10 µg mL−1. Free 
DOX, PDMs, and IR780-PDMs showed similar cytotoxicity to the 
tumor cells under the condition of pH 7.4. However, compared 
with the viabilities of cells that separately incubated with PDMs 
and IR780-PDMs at pH 6.6, the acidic environment gave rise to 
a lower survival rate, the reason of which might be the fact that 
more positive drug formulation had entered into cells. At both of 
the two pH values, the cell viabilities of IR780-PDMs with NIR 
laser were lower than those without NIR laser, and they decreased 
in pace with the increase of the concentration of IR780.
In order to further evaluate the photodamage effect of IR780-
PDMs, A549 cells were stained by calcein AM/PI after the 
treatment in different conditions, and detected by fluorescence 
microscopy (Figure 3B). Live cells produce strong green fluo-
rescence, while dead cells produce strong red fluorescence.[22] 
Whether with or without laser, there were almost all green 
spots in the control group. However, more red spots were 
observed in the IR780-PDMs group with laser radiation, which 
proved the obvious photothermal toxicity of IR780-PDMs to 
cells. The Annexin V-FITC/PI staining was employed to detect 
Adv. Funct. Mater. 2020, 30, 1906309
Figure 2. A) TEM image of PDMs, assembled by P-DOX at pH 7.4. B) Scattering intensity of P-DOX at different concentration. C) pH-dependent size 
change of PDMs. D) TEM image of P-DOX, dissociating from PDMs at pH 6.6. E) Zeta potential of PDMs at pH 7.4, 6.6, and 5.0. F) DLS of IR780-
PDMs. G) Infrared thermal images and H) temperature changes of IR780-PDMs (equivalent to 6 or 12 mg mL−1 IR780) in response to laser irradiation 
(808 nm, 1 W cm−2) within 300 s. I) In vitro release of DOX from IR780-PDMs at 37 °C.
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the distribution of apoptotic cells (Figure 3C,D). Laser radiation 
induced significant cell apoptosis with apoptotic rates of 75.2% 
at pH 7.4 and 89.9% at pH 6.6, which were 1.3-fold and 1.4-fold 
higher than those of IR780-PDMs group without laser radia-
tion at the corresponding pH conditions, respectively. Hence, it 
is clear that IR780-PDMs are capable of promoting tumor cell 
apoptosis by synergistic chemo-photothermal treatment.
The cellular uptakes of IR780-PDMs at pH 7.4 and 6.6 were 
evaluated by confocal laser scanning microscopy (CLSM) with 
the fluorescence intensities of DOX and IR780, respectively. 
As shown in Figure 4A, after incubation with IR780-PDMs 
at acidic pH for 1 h, the strong red fluorescence of DOX and 
green fluorescence of IR780 can be clearly observed in cells. 
Furthermore, these endocytosed carriers rapidly passed through 
lysosomes, and released DOX to nucleus. During the entire 
period of incubation time, the fluorescence signals of IR780-
PDMs treatment at pH 6.6 were much stronger than those at 
pH 7.4. In addition, flow cytometry data further exhibited that 
the internalization of IR780-PDMs was much faster at pH 6.6 
(Figure 4B,C). Considering the protonation of PDEA blocks 
and the disassembly of IR780-PDMs in acidic environment, the 
possible reasons of these phenomena can be: 1) positive surface 
charge mediates more carriers entering into cells via the inter-
action with the negative cell membrane;[23] 2) size-dependent 
endocytosis accelerates the internalization of smaller ones.[24]
2.4. Tumor Penetration of IR780-PDMs
Multicellular spheroids (MCSs), as 3D models which can accu-
rately reflect the complex in vivo microenvironment, have been 
used in many research areas, including hepatotoxicity, neu-
rology, and cancer biology.[25] The intratumoral penetration of 
IR780-PDMs was evaluated through co-incubation with A549 
MCSs at different pH for 4 h. The maximal sections of MCSs 
were monitored by CLSM. After the treatment at pH 7.4, the 
red and green fluorescence mostly located at the marginal area 
of MCSs, while signals were barely observed in the interior of 
spheroid (Figure 5A). By contrast, these fluorescence signals 
distributed inside MCSs at pH 6.6, which indicated that the 
Adv. Funct. Mater. 2020, 30, 1906309
Figure 3. A) Viability of A549 cells incubated with different drug formulations with and without laser irradiation (1 W cm−2, 5 min). *p < 0.05, 
**p < 0.01, ***p < 0.001. B) Fluorescence images and C) apoptosis assay of A549 cells treated with IR780-PDMs with and without laser irradiation 
(1 W cm−2, 5 min), PBS was used as a control. Q1: necrotic cells, Q2: later apoptotic cells, Q3: early apoptotic cells, Q4: living cells. Scale bar: 25 µm. 
D) The relative changes of the percentage in each apoptosis quadrant.
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penetration depth was also correlated with the dissociation 
of IR780-PDMs in acidic environment. Plots of the fluores-
cence intensity to the distance measured from the spheroid 
central axis reveal that the penetration depth of IR780-PDMs 
into MCSs at pH 6.6 was much deeper than that at pH 7.4 
(Figure 5B).
To better demonstrate the penetration ability, the diffusion 
of IR780-PDMs into tumor was investigated by exposing them 
to excised cancer tissue in medium at pH 6.6 and pH 7.4, 
respectively. As shown in Figure 5C, IR780-PDMs exhibited 
minimal penetration ability at physiological pH, since the fluo-
rescence was mostly located on the tumor edge. Whereas, more 
fluorescence signals of DOX and IR780 were observed from 
the inside of the excised tumor at acidic pH. The penetration 
ability can be enhanced by the dissociation of IR780-PDMs into 
small-size conjugates, which is consistent with the results of 
former researches.[18b,26] Further, the in vivo tumor penetration 
was investigated by the intravenous injection of IR780-PDMs 
into tumor-bearing nude mice (Figure 5D). Due to the pH-trig-
gered dissociation of IR780-PDMs at the tumor tissue, the deep 
penetration can be clearly observed from the frozen sections 
of solid tumor which was collected at 24 h postinjection. After 
extravasation from the vessels, the fluorescence of DOX and 
IR780 was spreaded over the entire tumor parenchyma.
2.5. Tumor-Targeted Imaging of IR780-PDMs
A549 tumor-bearing BALB/c nude mice after intravenous 
injection with IR780+P-DOX and IR780-PDMs were cap-
tured by NIR-fluorescence/PA imaging system to evaluate the 
tumor-targeting efficiency in vivo. As depicted in Figure 6A, 
the fluorescence of IR780 in both groups almost distributed 
all over the body of mice at 2 h postinjection. For the IR780-
PDMs group, the fluorescence signal at the tumor site gradu-
ally increased and finally reached the maximum level at 24 h 
postinjection. Moreover, the strong signal was sustained in the 
subsequent period of testing time, which indicates that IR780-
PDMs can effectively achieve tumor-specific targeting without a 
ligand. In contrast, the tumor fluorescence intensity in the mice 
treated with IR780+P-DOX was notably weak and decreased 
along with time after 24 h postinjection, the reason of which 
is their rapid clearance from the blood circulation. To further 
confirm the tumor-targeting ability and quantitatively estimate 
the biodistribution of drug-loading nanocarriers, tumors and 
the major organs (heart, liver, spleen, lung, and kidney) were 
collected at 36 h postinjection for ex vivo NIR- fluorescence 
imaging (Figure 6B). In contrast with other tissues, the IR780-
PDMs group showed the highest fluorescence intensity at the 
tumor site, which was also 2.4 times stronger than that of the 
IR780+P-DOX group (Figure 6C).
PA is an emerging biomedical imaging technique based on 
the transition from absorbed photons to acoustic waves which 
are then detected and processed to form an image.[27] In our 
system, IR780, a superb PA contrast agent, was used to visu-
alize the tumor morphology in vivo. As shown in Figure 6D, 
after intravenous injection of PBS, the tumor barely exhibited 
PA signal. On the contrary, the PA signals in the IR780+P-
DOX and IR780-PDMs groups displayed a distinct increase at 
24 h postinjection owing to the enrichment of IR780 in tumor 
tissues. More importantly, the PA signal of the IR780-PDMs 
group was 4.4-fold and 2.6-fold higher than that of the PBS 
and the IR780+P-DOX groups (Figure 6E), respectively. Such 
a strong signal was all over the whole tumor, which can be 
attributed to the great tumor accumulation and permeation of 
IR780-PDMs.
Adv. Funct. Mater. 2020, 30, 1906309
Figure 4. A) CLSM images and B,C) Flow cytometry analysis of A549 cells incubated with IR780-PDMs at pH 6.6 or 7.4 for 1 and 2 h. DAPI: blue signal, 
DOX: red signal, LysoTracker: yellow signal, IR780: green signal. Scale bar: 25 µm.
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2.6. Circulation Half-Life and Tumor Retention of IR780-PDMs
To investigate the effect of the π–π stacking of DOX and IR780 
on the circulation half-life of polymeric micelles, the non-
conjugated counterparts (IR780-Ms) self-assembled by block 
polymer (PDEA-b-POtEGMA) were used as the control group. 
The synthetic route of PDEA-b-POEGMA and the preparation 
process of IR780-Ms are presented in Figure S9 (Supporting 
Information). The interaction between IR780 and nanoparti-
cles were analyzed by UV-vis spectra (Figure S10, Supporting 
Information). After loading IR780, a strong characteristic 
adsorption peak of IR780-PDMs appeared at 799 nm, with a 
red shift from 792 nm (free of IR780 and IR780-Ms), which 
was caused by the formation of π–π stacking interaction.[28] 
Meanwhile, the red shift also appeared in the adsorption peak 
of DOX. In addition, the CMC and in vitro stability of IR780-
Ms were investigated as well. As shown in Figure S11 (Sup-
porting Information), the formation of the micelles requires a 
relatively high concentration (0.047 mg mL−1) of PDEA-b-PO-
EGMA. Moreover, a drastic particle size variation of IR780-Ms 
in 10% FBS medium was observed within 48 h. Compared 
with IR780-PDMs, the nonconjugated micelles are unstable in 
complex surrounding.
The fluorescence of collected blood and the relative plasma 
levels of IR780 at different time points after the intravenous 
injections of free IR780, IR780-Ms, and IR780-PDMs are illus-
trated in Figure 7A,B. The fluorescence signals of free IR780 
and IR780-Ms were rapidly eliminated from the systemic cir-
culation, indicating that IR780 was very likely leaked from 
IR780-Ms and consequently metabolized from kidney. As being 
expected, IR780-PDMs displayed an evidently long elimination 
half-life (t1/2β = 22.6 h), which was about 11.9-fold and 8.4-fold 
longer than that of IR780 and IR780-Ms, respectively. These 
results implied the superior stability of IR780-PDMs which pre-
vented the early drug leakage, and prolonged the blood circula-
tion time.
The tumor accumulation and retention of free IR780, IR780-
Ms, and IR780-PDMs were further evaluated by an IVIS Spec-
trum Imaging System (Figure 7C). IR780-PDMs exhibited great 
passive targeting ability and persisted to permeate into the 
tumor tissue over several days, which are beneficial to main-
tain effective drug concentration, and then reduce the dosing 
frequency. However, both free IR780 and IR780-Ms showed 
less tumoral uptake and shorter local retention time. Figure 7D 
reveals that the fluorescence intensity of excised tumor of the 
IR780-PDMs group at 6 days postinjection was nearly 9.7-fold 
Adv. Funct. Mater. 2020, 30, 1906309
Figure 5. A) CLSM images of A549 MCSs for the ex vivo penetration test. The MCSs were incubated with IR780-PDMs for 4 h at pH 6.6 or 7.4. Scale 
bar: 100 µm. B) Plots of the penetration depth of DOX and IR780 into A549 MCSs treated with IR780-PDMs. C) Frozen sections of A549 tumors after 
ex vivo incubation with IR780-PDMs solution for 4 h at pH 6.6 or 7.4. Scale bar: 200 µm. D) Frozen section of A549 tumors after the intravenous 
administration of IR780-PDMs at 24 h postinjection. Arrows: CD31 antibody-labeled vascular endothelial cells. Scale bar: 100 µm.
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and 6.5-fold higher than that of the free IR780 and IR780-Ms 
groups, respectively. Hence, through the π–π stacking interac-
tion, the small-molecule drugs were locked into the polymeric 
micelles, which obviously prolonged the blood circulation and 
further enhanced the tumor accumulation and retention of 
IR780-PDMs.
2.7. Chemo-Photothermal Synergistic Therapy and Biosafety  
of IR780-PDMs
Encouraged by the high photodamage and excellent tumor-tar-
geting of IR780-PDMs, the in vivo photothermal experiments 
on A549 tumor-bearing mice were carried out at 24 h postin-
jection after treatment with PBS, IR780+P-DOX, or IR789-
PDMs (Figure 8A). After 2 min of laser irradiation, the tumor 
of mice treated with IR789-PDMs reached a temperature over 
45 °C. When the tumor site was exposed to 808 nm NIR laser 
for 5 min, the temperature for the IR789-PDMs group reached 
the maximum of 48.9 °C, with an increment of 16.9 °C. It has 
been demonstrated that the cancer cells, which are particularly 
vulnerable to heating, can be selectively killed by the nanocar-
rier-mediated hyperthermia with minimal damage to the sur-
rounding normal cells.[29] However, the tumor temperature only 
reached 40.1 °C for the IR780+P-DOX group and 36.0 °C for 
the PBS group (ΔT < 8 °C), which are far insufficient to induce 
cell necrosis. The tumor temperature decreased after turning 
off the irradiation (Figure S12, Supporting Information).
As shown in Figure 8B, a clear injury can be observed at 
the tumor site of mice treated with IR780-PDMs under laser 
irradiation. All of the tumors disappeared without recurrence 
accompanying with the shedding of solid scar and the regen-
eration of normal tissue. As for the another two-treated groups, 
there was no significant photothermal damage to the tumor 
tissue. The chemo-photothermal antitumor efficacy of IR780-
PDMs was further investigated on A549 tumor-bearing mice. 
Figure 8C shows the tumor growth curves of mice treated with 
PBS, DOX, IR780+P-DOX, and IR780-PDMs, respectively. In 
the PBS-treated group, the tumor volumes grew rapidly and 
reached 1026 mm3 at 18 days after the treatment, which can 
hardly be inhibited by the NIR laser irradiation. The groups 
treated by DOX and IR780+P-DOX with or without NIR laser 
irradiation showed negligible inhibition on tumor growth, 
which is because of the lower accumulation of DOX and IR780 
at the tumor site. By contrast, 45.7% tumor suppression was 
obtained in the group treated with IR780-PDMs. Being com-
bined with NIR laser irradiation, the tumor growth was notice-
ably inhibited, which showed a suppression ration as high as 
97.6% after the entire treatment cycle. The above results were 
further confirmed by the tumors weight at the end of the 
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Figure 6. A) NIR fluorescence imaging of A549 tumor-bearing BALB/c nude mice taken at 2, 12, 24, and 36 h after intravenously administrated with 
IR780+P-DOX or IR780-PDMs. B) Ex vivo NIR fluorescence imaging and C) Quantitative analysis of the harvested organs and tumors at 36 h postinjec-
tion. D) PA imaging and E) PA intensity of tumor site after the intravenous administration of IR780+P-DOX or IR780-PDMs at 24 h postinjection. PBS 
as the control group. **p < 0.01, ***p < 0.001.
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therapies (Figure S13, Supporting Information). Hematoxylin 
and eosin (H&E) and TUNEL (terminal deoxynucleotidyl trans-
ferase-mediated dUTP nick end labeling) staining were used to 
estimate the cell apoptosis in tumor tissues (Figure 8D). Dif-
ferent from the typically histologic characteristics of malignant 
tumors such as hyperchromatic nuclei and scant cytoplasm,[30] 
obvious nuclear shrinkage and fragmentation were observed in 
the tumor slices of the group treated by IR780-PDMs with laser 
irradiation. Compared with the traditional drug-loaded nanocar-
riers for sole or synergistic tumor therapy,[12a,31] IR780-PDMs 
for chemo-photo thermal therapy presented a superior tumor 
elimination effect at low dose as a result of the long-acting 
intensive therapeutic strategy.
The potential biosafety of IR780-PDMs was also evaluated. 
As shown in Figure 8E, the body weights of the mice slightly 
increased within an 18 days therapy. Moreover, the major organs 
of the mice at the end of the treatment, including heart, liver, 
spleen, lung, and kidney, were further analyzed by histological 
examination. The chemo-photothermal effects of IR780-PDMs 
caused no apparent pathological abnormalities or lesions 
(Figure S14, Supporting Information). These data suggested that 
IR780-PDMs have good biocompatibility to living animals and 
tremendous potential to be used as a promising antitumor agent.
3. Conclusion
In summary, we have successfully developed a smart drug-dye-
based micelle to optimize tumoral delivery efficiency and reduce 
systemic side effect of the drugs. Through the self-assembly 
of polymeric conjugates and π–π stacking of small-molecule 
drugs, IR780-PDMs were constructed for chemo-photothermal 
therapy. Long-circulation of IR780-PDMs led to the enhance-
ment of tumor accumulation and retention (up to 6 days), and 
consequently the extension of effect time against tumor cells. 
Furthermore, the enhanced penetration and controllable drug 
release of IR780-PDMs, due to their size conversion and bond 
fracture in response to tumor acidic microenvironment, were 
confirmed by both in vitro and in vivo experiments. IR780-
PDMs showed high delivery efficiency, excellent synergistic 
antitumor effect, and fairly good biosafety after a single-dose 
intravenous injection into mice. Overall, this work presents 
a brand-new strategy for long-acting intensive cancer therapy 
which can overcome multiple biological obstacles.
4. Experimental Section
Materials: PFMA was synthesized according to the previous report.[32] 
The synthetic raw materials, 4-cyano-4-(phenylcarbonothioylthio) 
pentanoic acid (CPAD), azodiisobutyronitrile (AIBN), OEGMA, DEA, 
and doxorubicin hydrochloride (DOX·HCl) were purchased from J&K 
(China). FBS, trypsin, and Ham’s F-12K medium were purchased 
from Gibco (USA). MTT, 4′,6-diamidino-2-phenylindole (DAPI), and 
Annexin V-FITC/PI apoptosis detection kit were obtained from Beyotime 
(China). LysoTracker Green DND-189 were purchased from Yesen 
(China). All reagents in analytical grade were used as received. The 
dialysis membranes (MWCO: 3500 Da) were obtained from Sangon 
Biotech (China). Milli-Q water was purified via the Milli-Q Plus System 
(Millipore, USA).
Figure 7. A) Fluorescence images of collected blood from mice at predesigned time after intravenous injection of free IR780, IR780-Ms, or IR780-
PDMs. B) Circulation kinetics of different drug formulations. C) NIR fluorescence imaging of A549 tumor-bearing BALB/c nude mice at different time 
posts after intravenous injection of free IR780, IR780-Ms, or IR780-PDMs. D) Fluorescence intensities of the harvested tumors at 6 days postinjection.
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Cells and Animals: Human non-small-cell lung cancer cells (A549), 
provided by Chinese Academy of Sciences, were grown in Ham’s F-12K 
supplemented with 10% FBS at 37 °C under 5% CO2 in ESCO cell 
incubator. Female BALB/c-nude mice (5 weeks old) and BALB/c mice 
(6 weeks old) were ordered from Shanghai JSJ Laboratory Animal Co., Ltd. 
(China). All animal experiments were performed in compliance with the 
Guidelines for Use and Care of Animals in Shanghai Jiao Tong University.
Synthesis of Copolymer Backbone: P(FPMA-co-DEA)-b-POEGMA was 
synthesized in two steps. First, CPAD (35 mg, 0.125 mmol), AIBN 
(8.2 mg, 0.5 mmol), DEA (2.775 g, 15 mmol), and FPMA (0.950 g, 
5 mmol) were dissolved in dry tetrahydrofuran (THF; 6 mL). The solution 
mixtures were subjected to five freeze-pump-thaw cycles and filled with 
argon in Schlenk tube. This sealed tube was immersed in a preheated 
oil bath at 65 °C for 12 h. The resultant mixture was dialyzed against 
dimethylformamide (DMF) to remove unreactive monomers. Then, 
the obtained P(FPMA-co-DEA) (0.5 g, 0.05 mmol), AIBN (4.1 mg, 
0.25 mmol), and OEGMA (1.5 g, 3 mmol) were dissolved in 4 mL of 
dry THF and degassed by performing five freeze-pump-thaw cycles. The 
reaction mixture was transferred into a preheated oil bath at 65 °C for 12 h. 
P(FPMA-co-DEA)-b-POEGMA was purified by dialysis as described above.
Fabrication of P-DOX: P(FPMA-co-DEA)-b-POEGMA (0.4 g) was 
dissolved in 2 mL of DCM. DOX·HCl (50 mg) and threefold molar 
triethylamine were dissolved in 2 mL of dimethyl sulfoxide for 2 h, and 
then dropwise added to the copolymer solution under stirring for an 
extra 16 h. The conjugates were isolated from the mixture by successive 
dialysis against sufficient DMF/deionized water and obtained by 
freeze-drying.
Preparation of IR780-PDMs: 5 mg of P-DOX was dissolved in 0.5 mL 
of acetone, and slowly injected into 5 mL of deionized water. 0.25 mg of 
IR780 with the concentration of 1 mg mL−1 in acetone was added to the 
conjugates. The final solution was kept stirring to evaporate the acetone 
completely, and then filtered through a 0.45 µm Millipore filter.
Characterization: GPC (Waters ACQUITY UPLC, USA) was used 
to detect the molecular weight of copolymers, using polymethyl 
methacrylate (PMMA) standard with a refractive index detector and 
DMF as the elution. The chemical structures of copolymers were 
recorded on 1H NMR (Bruker, Germany), FT-IR (Thermo Nicolet, USA), 
and UV-vis absorption spectra (Shimadz, Japan). DLS and zeta potential 
were performed by a Malvern Nanozetasizer (England). The scattering 
intensity of copolymer was monitored by NanoBrook Omni (USA). The 
morphologies were determined by TEM (JEOL, Japan) at 120 KV.
150 µL of IR780-PDMs solutions (IR780-equivalent dose: 6 and 
12 µg mL−1) were placed in centrifuge tubes and exposed to NIR 
irradiation (808 nm continuous-wave diode laser, 1 W cm−2) for 
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Figure 8. In vivo chemo-photothermal therapy. A) Infrared thermal images and B) representative images of mice treated with PBS, IR780+P-DOX, or 
IR780-PDMs. At 24 h postinjection, the mice were irradiated by 808 nm laser with the power of 1 W cm−2. C) Tumor growth curves and E) body weight 
variation of A549 tumor-bearing mice treated with PBS, DOX, IR780+P-DOX, or IR780-PDMs. Laser: 808 nm, 1 W cm−2, 5 min. (dose: 1.5 mg kg−1 
DOX and 0.8 mg kg−1 IR780). **p < 0.01, ***p < 0.001. D) H&E and TUNEL staining images of tumor slices after different treatment. Scale bar: 100 µm.
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5 min. PBS was also irradiated as a control. The temperature changes at 
different irradiation times were monitored by an IR thermal camera and 
analyzed using IR Flash thermal imaging software.
The fluorescence of DOX at excitation wavelength of 480 nm and 
IR780 at excitation wavelength of 720 nm were detected by F-4600 
spectrofluorometer (Hitachi, Japan). The DL was calculated by the 
following formula: DL (%) = (weight of loaded drug)/ (total weight of 
micelles and drug) × 100%.
In Vitro Chemodrug Release Profile: The DOX and IR780 release 
from IR780-PDMs was studied by the dialysis method. 1 mL of IR780-
PDMs solution was placed into a dialysis membrane with or without 
laser irradiation (1 W cm−2, 5 min), and then incubated in 20 mL of 
PBS (pH 5.0, 6.6, or 7.4). The release experiments were carried out 
in an incubator under gentle sharking (100 rpm) at 37 °C. 0.5 mL of 
supernatant was taken at predetermined time intervals for detection, 
and then replaced by an equal volume of fresh release medium. The 
cumulative quantities of the DOX and IR780 released from IR780-PDMs 
were calculated based on the fluorescence emission intensity.
Cytotoxicity and Apoptotic Assay: A549 cells were seeded in 96-well 
plates at a density of 1 × 104 cells per well overnight. 150 µL of fresh 
medium containing P(DEA-co-FPMA)-b-POEGMA, DOX, PDMs, or 
IR780-PDMs (DOX-equivalent dose: 0.5–10 µg mL−1, IR780-equivalent 
dose: 0.27–5.32 µg mL−1) was separately added for incubation at pH 6.6 
or 7.4 for 12 h. All the cells were washed twice with PBS, and treated 
with or without laser irradiation (1 W cm−2, 5 min). After another 12 h 
of incubation, the cellular cytotoxicity was determined by MTT assay. 
The absorbance of purple formazan crystals produced by live cells was 
recorded on Microplate Reader (Model 680, Bio-Rad). The relative cell 
viability was determined by comparing with the untreated cells.
Apoptosis induced by IR780-PDMs was detected using Annexin 
V-FITC/PI apoptosis detection kit. A549 cells were seeded in 24-well 
plates at 6 × 104 cells per well overnight before the exposure to IR780-
PDMs (DOX-equivalent dose: 5 µg mL−1, IR780-equivalent dose: 
2.66 µg mL−1) at pH 6.6 and 7.4 for 12 h, respectively. All the cells were 
washed with sufficient PBS, and irradiated with or without a power 
of 1 W cm−2 808 nm laser for 5 min. The following procedures were 
performed in accordance with the manufactures’ protocols after an extra 
12 h of incubation. The apoptotic and necrotic cell distributions were 
analyzed by FlowJo software.
The photodamage of cells caused by the carriers was visually 
observed by fluorescence microscopy. A549 cells were incubated with 
IR780-PDMs (DOX-equivalent dose: 5 µg mL−1, IR780-equivalent dose: 
2.66 µg mL−1) at pH 6.6 or 7.4 for 12 h, and then washed with PBS twice. 
After being treated by the same laser exposure process as previous 
and incubation, the cells were stained with a mixture of Calcein-AM 
(2.0 × 10−6 m)/PI (1.5 × 10−6 m) and then observed by a Lecia CTR6000 
fluorescence microscopy.
Cellular Uptake: A549 cells were seeded in a 24-well plate covered with 
glass at a density of 6 × 104 cells per well overnight. Subsequently, the 
cells were treated with IR780-PDMs (DOX-equivalent dose: 5 µg mL−1, 
IR780-equivalent dose: 2.66 µg mL−1) at pH 6.6 and 7.4 for 1 and 2 h, 
respectively. Afterward, the cells were washed twice with PBS, and then 
stained with LysoTracker to label lysosome. The nuclei of the cells were 
stained with DAPI, and then observed by a TCS SP8 STED confocal 
fluorescence microscopy (Leica, German). The intracellular uptake of 
IR780-PDMs was analyzed by flow cytometry.
Penetration Assay: A549 cells were 3D cultured by using the Corning 
spheroid microplate in accordance with the guidelines of forming MCSs. 
The medium was separately adjusted to pH 6.6 and 7.4, followed by 
the addition of IR780-PDMs (DOX-equivalent dose: 5 µg mL−1, IR780-
equivalent dose: 2.66 µg mL−1). After 4 h incubation, MCSs were 
thoroughly washed with PBS and monitored by Leica TCS SP8 CLSM 
Z-stack scanning.
A549 tumor-bearing mice were established by subcutaneously 
injecting 5 × 106 of A549 cells into the right flank of each mouse. To 
analyze ex vivo tumor penetration, the tumors were collected when their 
average volume had reached 300–400 mm3. The excised tumors were 
cultured for 4 h with IR780-PDMs (DOX-equivalent dose: 5 µg mL−1, 
IR780-equivalent dose: 2.66 µg mL−1) after the medium was adjusted to 
pH 6.6 or pH 7.4. To analyze in vivo tumor penetration, tumor-bearing 
mice were administered via intravenous injection with IR780-PDMs 
at a dose of 1.5 mg DOX kg−1 and 0.8 mg IR780 kg−1 for 24 h. Frozen 
sections of tumors were harvested. The nuclei of the cells were stained 
with DAPI. The fluorescence of edge and inside region of each tumor 
section were imaged using Nikon biological microscope.
In Vivo Imaging and Biodistribution Analysis: When the tumor volume 
of A549 tumor-bearing mice reached 100–150 mm3, these mice were 
intravenously injected with IR780+P-DOX and IR780-PDMs at a dose of 
0.4 mg IR780 kg−1, respectively. The fluorescent images at predetermined 
time intervals (2, 12, 24, and 36 h) were captured by an in vivo IVIV 
Lumina II optical imaging system (Caliper, USA). The major organs 
(heart, liver, spleen, lung, and kidney) and tumors from the above-treated 
tumor-bearing mice were collected for ex vivo imaging. To capture the 
in vivo photoacoustic signal at the focal depth of 5 mm at the tumor 
site after intravenous administration of PBS, IR780+P-DOX, or IR780-
PDMs for 24 h, a photoacoustic imaging system (VEVO LAZR-X, Fujifilm 
VisualSonics, USA) with laser at a wavelength of 720 nm was used.
Circulation Half-Life and Tumor Retention Study: Free IR780 was 
dissolved in cremophor EI and alcohol mixed solution (50:50, v/v), 
and then diluted by PBS. The preparation procedure of IR780-Ms was 
similar to the IR780-PDMs. PDEA-b-POEGMA and IR780 were dissolved 
in acetone, and then slowly injected into deionized water. The stock 
solution was stirred to evaporate the acetone completely. Female BALB/c 
mice were intravenously administered with free IR780, IR780-Ms, or 
IR780-PDMs at a dose of 0.8 mg IR780 kg−1, respectively. 10 µL of blood 
sample from each mouse was collected into heparinized centrifuge 
tube at each of the following time points: 0.2, 0.5, 1, 2, 4, 8, 12, and 
24 h after dosing. All blood samples were stored at 4 °C before analysis. 
The fluorescence intensity of each sample in the centrifuge tube was 
measured using a Bruker F PRO imaging system (Billerica, MA, USA). 
The percent injected dose (%ID) was calculated using the following 
equation: %ID = (dose in blood)/ (injected dose) × 100%.
A549 tumor-bearing mice were intravenously injected with free IR780, 
IR780-Ms, and IR780-PDMs at a dose of 0.4 mg IR780 kg−1, respectively. 
The fluorescent images at predetermined time intervals were captured 
by an in vivo IVIV Lumina II optical imaging system to evaluate the 
tumor retention of the drug formulations.
Chemo-Photothermal Synergistic Therapy: When the tumor volumes 
reached 100–150 mm3, A549 tumor-bearing mice were randomly 
divided into seven groups (n = 3), and separately administered via 
tail vein injection with PBS, DOX, IR780+P-DOX, and IR780-PDMs at 
a dose of 1.5 mg DOX kg−1 and 0.8 mg IR780 kg−1 (designated as the 
day 0). In the case of PBS, IR780+P-DOX, and IR780-PDMs groups, the 
tumors were exposed to the NIR laser with 1 W cm−2 for 5 min at 24 h 
postinjection. The temperature and IR images were recorded in real time 
using an infrared camera. Afterward, the tumor size and body weight 
of each mouse were monitored and recorded every 2 days. The tumor 
size was measured by a vernier caliper, and the tumor volume (V) was 
estimated using the formula: V = (length × width2)/2. The isolated solid 
tumors from the nude mice were weighted at the end of treatment.
Histological Analysis: The harvested tumors and major organs of 
mice were fixed in 5% paraformaldehyde solution and then embedded 
into paraffin. These tissues were sectioned at a thickness of 5 µm, and 
separately stained with H&E and TUNEL to assess the histological 
alteration.
Statistical Analyses: Data were given as mean ± standard deviation 
(n ≥ 3). The statistical significance of these data was determined by 
Student’s T-test. p < 0.05 was considered as significant, and p < 0.01 
was considered as highly significant (GraphPad Prism, version 7.0).
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